Age, Biography and Wiki

Brent Saunders was born on 6 February, 1970, is an American biopharma executive and entrepreneur. Discover Brent Saunders's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is he in this year and how he spends money? Also learn how he earned most of networth at the age of 54 years old?

Popular As N/A
Occupation Chairman and CEO of Bausch + Lomb Founder of Vesper Healthcare Acquisition Chairman of The Beauty Health Company Chairman of Hugel America
Age 54 years old
Zodiac Sign Aquarius
Born 6 February, 1970
Birthday 6 February
Birthplace N/A
Nationality

We recommend you to check the complete list of Famous People born on 6 February. He is a member of famous executive with the age 54 years old group.

Brent Saunders Height, Weight & Measurements

At 54 years old, Brent Saunders height not available right now. We will update Brent Saunders's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.

Physical Status
Height Not Available
Weight Not Available
Body Measurements Not Available
Eye Color Not Available
Hair Color Not Available

Dating & Relationship status

He is currently single. He is not dating anyone. We don't have much information about He's past relationship and any previous engaged. According to our Database, He has no children.

Family
Parents Not Available
Wife Not Available
Sibling Not Available
Children Not Available

Brent Saunders Net Worth

His net worth has been growing significantly in 2023-2024. So, how much is Brent Saunders worth at the age of 54 years old? Brent Saunders’s income source is mostly from being a successful executive. He is from . We have estimated Brent Saunders's net worth, money, salary, income, and assets.

Net Worth in 2024 $1 Million - $5 Million
Salary in 2024 Under Review
Net Worth in 2023 Pending
Salary in 2023 Under Review
House Not Available
Cars Not Available
Source of Income executive

Brent Saunders Social Network

Instagram
Linkedin
Twitter
Facebook
Wikipedia
Imdb

Timeline

1970

Brent Saunders (1970 (age 45)) is an American biopharma executive and entrepreneur who is the chairman and CEO of the health company Bausch & Lomb.

He helped lead various mergers and acquisitions, including the mergers between Merck and Schering-Plough, the acquisition of Bausch + Lomb by Valeant Pharmaceuticals, and the $63 billion acquisition of Allergan by Abbvie.

He is the founder of special-purpose acquisition company (SPAC) Vesper Healthcare Acquisition.

Saunders is also executive chairman of medical aesthetics companies The Beauty Health Company and Hugel America.

Saunders was born in 1970 (age 45) to Charles and Sheila Saunders, a urologist and social worker.

1988

He grew up in the Lehigh Valley region of eastern Pennsylvania, with a twin brother Wayne and sister Reed, and graduated from Parkland High School in South Whitehall Township, Pennsylvania in 1988.

1992

He attended the University of Pittsburgh, where he was president of the student government board, and graduated in 1992 with a bachelor's degree in economics and East Asian studies.

1996

In 1996, he received MBA and J.D. degrees from Temple University in Philadelphia.

In 1996, while attending law school, Saunders started working part time at Jefferson Health as a compliance officer.

2000

In 2000, Saunders joined PricewaterhouseCoopers as a healthcare compliance manager, and became partner and head of the firm's compliance business advisory services group.

2003

In October 2003, Saunders was hired as senior vice president of global compliance and business practices at Schering-Plough, a pharmaceutical company.

2007

In mid-2007, he became president of consumer health care at Schering-Plough, with responsibility for a business unit of products including Coppertone, Dr. Scholl's, and Claritin.

2009

In 2009, Saunders led the integration team of Schering-Plough's merger with Merck.

2010

In 2010, Saunders was appointed chief executive officer Bausch & Lomb, an eye health company.

In 2010 he was appointed to the Federal Reserve advisory board.

2013

In 2013, as CEO of Bausch + Lomb, he oversaw its acquisition by Valeant Pharmaceuticals, now known as Bausch Health, for $8.7 billion.

He joined Valeant in an advisory role to assist with the transition.

In October, Saunders joined pharmaceutical company Forest Laboratories as CEO.

2014

In May 2014, Saunders was named chief executive officer of Actavis, a pharmaceutical company, after the company acquired Forest Laboratories.

In November, Saunders negotiated Actavis' merger with Allergan, a pharmaceutical company, for a reported $70.5 billion.

The new combined company took the Allergan name.

2015

In February 2015, Saunders appeared on the cover of Forbes magazine, where he was named as "Wall Street's Drug Dealer".

2019

In May 2019, Saunders survived a proposal brought by hedge fund Appaloosa Management to split Allergan's chairman and CEO roles.

In June, pharmaceutical company Abbvie acquired Allergan for $63 billion.

2020

In June 2020, Saunders joined the board of BridgeBio Pharma, a company founded with an IPO in 2019.

In September, Saunders’ special-purpose acquisition company Vesper Healthcare Acquisition publicly launched, and raised $400 million.

Filings indicated that Saunders owned 20% of the company after the SPAC sale.

In December, Saunders made his first deal with Vesper, acquiring HydraFacial, a beauty treatment company, for $1.1 billion.

In May 2021, Vesper's HydraFacial deal closed, and the new company was renamed The Beauty Health Company, with Saunders taking the role of executive chairman.

He also served as interim CEO until February 2022.

In June 2022, Saunders was named to the board of medical aesthetics company Hugel America, an affiliate of South Korea-based Hugel Inc.

In March 2023, Saunders returned to Bausch + Lomb as CEO and chairman.

In June, Saunders signed his first deal as CEO, purchasing dry eye drug Xiidra from Novartis for $1.75 billion.